Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by HealthInvest Partners AB

HealthInvest Partners AB grew its stake in Cabaletta Bio, Inc. (NASDAQ:CABA) by 46.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 247,454 shares of the company’s stock after purchasing an additional 78,932 shares during the period. HealthInvest Partners AB owned about 0.51% of Cabaletta Bio worth $554,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in CABA. Fred Alger Management LLC boosted its holdings in Cabaletta Bio by 63.3% during the third quarter. Fred Alger Management LLC now owns 4,119,394 shares of the company’s stock worth $19,444,000 after buying an additional 1,596,512 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Cabaletta Bio in the third quarter worth about $3,150,000. Walleye Capital LLC boosted its stake in shares of Cabaletta Bio by 111.6% during the 3rd quarter. Walleye Capital LLC now owns 401,982 shares of the company’s stock worth $1,897,000 after acquiring an additional 212,025 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Cabaletta Bio by 12.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,644 shares of the company’s stock worth $5,168,000 after acquiring an additional 124,071 shares in the last quarter. Finally, Jennison Associates LLC grew its position in shares of Cabaletta Bio by 1.6% during the 3rd quarter. Jennison Associates LLC now owns 5,632,681 shares of the company’s stock valued at $26,586,000 after acquiring an additional 86,214 shares during the period.

Analyst Ratings Changes

A number of brokerages have issued reports on CABA. Evercore ISI downgraded Cabaletta Bio from an “outperform” rating to an “inline” rating and lowered their price target for the stock from $15.00 to $6.00 in a research report on Friday, December 20th. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. William Blair reissued an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. Wells Fargo & Company cut shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $12.00 to $6.00 in a research report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Cabaletta Bio currently has a consensus rating of “Buy” and a consensus target price of $22.71.

Cabaletta Bio Stock Performance

Shares of CABA stock opened at $2.05 on Monday. Cabaletta Bio, Inc. has a fifty-two week low of $1.76 and a fifty-two week high of $24.85. The stock’s fifty day moving average is $2.42 and its two-hundred day moving average is $3.54. The firm has a market capitalization of $99.96 million, a P/E ratio of -0.95 and a beta of 2.47.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.